Daniela Faria-Guimarães Selected Research

N-Methylaspartate (NMDA)

1/2024

Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniela Faria-Guimarães Research Topics

Disease

4	Major Depressive Disorder (Major Depressive Disorders) 01/2024 - 01/2022
2	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2024 - 03/2022
1	Mental Disorders (Mental Disorder) 01/2024
1	Autistic Disorder (Autism) 01/2023
1	Treatment-Resistant Depressive Disorder 01/2023
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2023

Drug/Important Bio-Agent (IBA)

3	EsketamineIBA 01/2024 - 01/2022
3	Antidepressive Agents (Antidepressants)IBA 01/2024 - 01/2022
3	Ketamine FDA LinkGeneric 01/2024 - 03/2022
1	Excitatory Amino AcidsIBA 01/2024
1	N-Methylaspartate (NMDA)IBA 01/2024
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2024
1	Glutamic Acid (Glutamate)FDA Link 01/2024
1	mesoglycanIBA 01/2023
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 03/2022

Therapy/Procedure

2	Therapeutics 01/2023 - 03/2022
1	Complementary Therapies (Alternative Medicine) 01/2023